L-Thyroxine Therapy for Older Adults With Subclinical Hypothyroidism and Hypothyroid Symptoms: Secondary Analysis of a Randomized Trial
- PMID: 32365355
- DOI: 10.7326/M19-3193
L-Thyroxine Therapy for Older Adults With Subclinical Hypothyroidism and Hypothyroid Symptoms: Secondary Analysis of a Randomized Trial
Abstract
Background: L-thyroxine does not improve hypothyroid symptoms among adults with subclinical hypothyroidism (SCH). However, those with greater symptom burden before treatment may still benefit.
Objective: To determine whether L-thyroxine improves hypothyroid symptoms and tiredness among older adults with SCH and greater symptom burden.
Design: Secondary analysis of the randomized, placebo-controlled trial TRUST (Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism Trial). (ClinicalTrials.gov: NCT01660126).
Setting: Switzerland, Ireland, the Netherlands, and Scotland.
Participants: 638 persons aged 65 years or older with persistent SCH (thyroid-stimulating hormone level of 4.60 to 19.9 mIU/L for >3 months and normal free thyroxine level) and complete outcome data.
Intervention: L-thyroxine or matching placebo with mock dose titration.
Measurements: 1-year change in Hypothyroid Symptoms and Tiredness scores (range, 0 to 100; higher scores indicate more symptoms) on the Thyroid-Related Quality-of-Life Patient-Reported Outcome Questionnaire among participants with high symptom burden (baseline Hypothyroid Symptoms score >30 or Tiredness score >40) versus lower symptom burden.
Results: 132 participants had Hypothyroid Symptoms scores greater than 30, and 133 had Tiredness scores greater than 40. Among the group with high symptom burden, the Hypothyroid Symptoms score improved similarly between those receiving L-thyroxine (mean within-group change, -12.3 [95% CI, -16.6 to -8.0]) and those receiving placebo (mean within-group change, -10.4 [CI, -15.3 to -5.4]) at 1 year; the adjusted between-group difference was -2.0 (CI, -5.5 to 1.5; P = 0.27). Improvements in Tiredness scores were also similar between those receiving L-thyroxine (mean within-group change, -8.9 [CI, -14.5 to -3.3]) and those receiving placebo (mean within-group change, -10.9 [CI, -16.0 to -5.8]); the adjusted between-group difference was 0.0 (CI, -4.1 to 4.0; P = 0.99). There was no evidence that baseline Hypothyroid Symptoms score or Tiredness score modified the effects of L-thyroxine versus placebo (P for interaction = 0.20 and 0.82, respectively).
Limitation: Post hoc analysis, small sample size, and examination of only patients with 1-year outcome data.
Conclusion: In older adults with SCH and high symptom burden at baseline, L-thyroxine did not improve hypothyroid symptoms or tiredness compared with placebo.
Primary funding source: European Union FP7.
Similar articles
-
Effect of Levothyroxine Therapy on the Development of Depressive Symptoms in Older Adults With Subclinical Hypothyroidism: An Ancillary Study of a Randomized Clinical Trial.JAMA Netw Open. 2021 Feb 1;4(2):e2036645. doi: 10.1001/jamanetworkopen.2020.36645. JAMA Netw Open. 2021. PMID: 33566107 Free PMC article. Clinical Trial.
-
Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism.N Engl J Med. 2017 Jun 29;376(26):2534-2544. doi: 10.1056/NEJMoa1603825. Epub 2017 Apr 3. N Engl J Med. 2017. PMID: 28402245 Clinical Trial.
-
Patient-Reported Satisfaction with Thyroid Hormone Replacement Therapy for Subclinical Hypothyroidism in Older Adults: A Pooled Analysis of Individual Participant Data from Two Randomized Controlled Trials.Thyroid. 2024 Jun;34(6):702-712. doi: 10.1089/thy.2023.0624. Epub 2024 May 3. Thyroid. 2024. PMID: 38661527 Clinical Trial.
-
Association of Thyroid Hormone Therapy With Quality of Life and Thyroid-Related Symptoms in Patients With Subclinical Hypothyroidism: A Systematic Review and Meta-analysis.JAMA. 2018 Oct 2;320(13):1349-1359. doi: 10.1001/jama.2018.13770. JAMA. 2018. PMID: 30285179 Free PMC article. Review.
-
The current debate over treatment of subclinical hypothyroidism to prevent cardiovascular complications.Int J Clin Pract. 2020 Jul;74(7):e13499. doi: 10.1111/ijcp.13499. Epub 2020 May 3. Int J Clin Pract. 2020. PMID: 32159256 Review.
Cited by
-
Increased thyroid stimulating hormone (TSH) as a possible risk factor for atherosclerosis in subclinical hypothyroidism.Thyroid Res. 2024 Jun 17;17(1):13. doi: 10.1186/s13044-024-00199-3. Thyroid Res. 2024. PMID: 38880884 Free PMC article. Review.
-
The different outcomes in the elderly with subclinical hypothyroidism diagnosed by age-specific and non-age-specific TSH reference intervals: a prospectively observational study protocol.Front Endocrinol (Lausanne). 2023 Nov 15;14:1242110. doi: 10.3389/fendo.2023.1242110. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38075041 Free PMC article.
-
Association between gestational blood lipids and TSH levels and pregnancy outcome of patients with subclinical hypothyroidism.Pak J Med Sci. 2023 May-Jun;39(3):721-725. doi: 10.12669/pjms.39.3.7150. Pak J Med Sci. 2023. PMID: 37250539 Free PMC article.
-
Hypothyroidism: The difficulty in attributing symptoms to their underlying cause.Front Endocrinol (Lausanne). 2023 Feb 6;14:1130661. doi: 10.3389/fendo.2023.1130661. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36814580 Free PMC article. Review.
-
Approach to adult patients with primary hypothyroidism in some special situations: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM).Arch Endocrinol Metab. 2022 Nov 17;66(6):871-882. doi: 10.20945/2359-3997000000545. Arch Endocrinol Metab. 2022. PMID: 36394484 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
